Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY2701439 in advanced HER2-expressing tumors
NCT04147819Phase 1Completed
- Sponsor
- Bayer
- Start
- Jul 2020
- Primary completion
- Aug 2023
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of 227th-trastuzumab in breast cancer, gastric cancer (GC), gastroesophageal junction cancer and 1 more (4 arms), sponsored by Bayer. Primary endpoints: Incidence of Treatment-Emergent Adverse Events, Severity of Treatment-Emergent Adverse Events and 2 more. Started Jul 2020; status: completed.
02
Drugs
227th-trastuzumab
03
Conditions
breast cancergastric cancer (GC)gastroesophageal junction cancersolid tumor
Beyond the preview
Go deeper on NCT04147819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04147819.